{
  "docId": "019dd923-5ca1-7489-b638-229be117d58e",
  "docSlug": "415e33cb189c4261",
  "documentTitle": "Impact of the US BIOSECURE Act on Biopharmas, Contract Services and Investors",
  "authorId": "LEK",
  "authorName": "L.E.K.",
  "documentKindSlug": "consulting-deck",
  "documentKindLabel": "Consulting deck",
  "sourceTypeSlug": "strategy_consulting",
  "sourceTypeLabel": "Strategy consulting",
  "presentationDate": null,
  "orientation": "landscape",
  "aspectRatio": 1.778,
  "pageNumber": 10,
  "pageCount": 13,
  "prevPage": 9,
  "nextPage": 11,
  "slideType": "data_table",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 36,
  "notes": "The chart displays survey results regarding the impact of the US BIOSECURE Act on partnering intentions.",
  "elementsJson": [
    "headline_text",
    "bar_chart_stacked",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5ca1-7489-b638-229be117d58e/10",
  "deckHref": "/decks/019dd923-5ca1-7489-b638-229be117d58e",
  "deckJsonHref": "/decks/019dd923-5ca1-7489-b638-229be117d58e.json",
  "deckAnchorHref": "/decks/019dd923-5ca1-7489-b638-229be117d58e#slide-10",
  "components": [
    {
      "bbox": {
        "h": 0.55,
        "w": 0.92,
        "x": 0.038,
        "y": 0.3
      },
      "kind": "chart",
      "text": "Stacked bar chart showing likelihood of partnering across 3 regions and 4 categories",
      "attrs": null,
      "subkind": "bar-stacked",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "564ea094-574e-47d8-877c-798d20073474",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.038,
        "y": 0.88
      },
      "kind": "disclaimer",
      "text": "*Survey question: Select, on a scale of 0 to 10, your likelihood of partnering with Chinese companies (0 is extremely low and 10 is extremely high)\nSource: L.E.K. 2024 Global Survey on Impact of US BIOSECURE Act",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "831eca13-bf28-46a3-8493-d3849447dfb4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.55,
        "x": 0.41,
        "y": 0.83
      },
      "kind": "legend",
      "text": "Likely (selected 7-10) | Neither likely nor unlikely (selected 4-6) | Unlikely (selected 0-3)",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ebe00048-48bd-4302-9eb2-d50547604b53",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "metric",
      "text": "Likelihood of partnering",
      "attrs": null,
      "subkind": "primary",
      "toolName": "Quantification",
      "toolSlug": "quantification",
      "confidence": null,
      "componentId": "019dd951-c7ca-701b-9cc7-539e6c4c300c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.85,
        "x": 0.038,
        "y": 0.06
      },
      "kind": "title",
      "text": "Global biopharmas still show high interest to partner with Chinese companies for product commercialization, more so than for clinical research, development and manufacturing",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6099cc0b-2984-4b65-8af8-05a95e418025",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.5,
        "x": 0.038,
        "y": 0.22
      },
      "kind": "title",
      "text": "Likelihood of partnering with Chinese companies in next three years after the US BIOSECURE Act *",
      "attrs": null,
      "subkind": "subtitle",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "909e3130-bc69-4632-acb5-fc3fa9a6dbdb",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 10,
      "from": 6,
      "beatId": "f22e8876-c901-4ea3-b100-be2f21d5e929",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Evidence & Proof",
      "beatSlug": "consultants-gambit-evidence-proof",
      "evidence": "The document presents data and findings from L.E.K.'s survey",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 10,
      "from": 4,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "04a5278d-7e5b-4b55-a8c7-0de1c16bfa6b",
      "evidence": "The document presents data on the potential impact of the Act on partnerships with Chinese companies",
      "position": 0,
      "objective": "Highlighting the consequences of not adapting to the US BIOSECURE Act",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}